Sasha is SR One’s General Counsel and Chief Compliance Officer based on the East Coast. Before joining SR One in 2022, she spent over 12 years at New Enterprise Associates as an in-house attorney focused on compliance, venture capital financings, and fund operations.

Jake is a partner at SR One focused on later-stage private and public biotech investments. He has over 25 years of life science experience and joined from NEA, where he was an investing partner from 2006 to 2019 and later a venture advisor.

Philip leads SR One's capital partnering effort and is based in London. He has over 15 years of experience in venture capital, private equity and real estate, and began his career at Cambridge Associates advising institutional investors on portfolio strategy and investments.

Rajeev is COO and managing partner of SR One in the San Francisco Bay Area. He joined in 2004 and invests in therapeutics and healthcare technology companies, drawing on operational and strategic experience.

Simeon is founder and CEO of SR One, co-founded after its 2020 spin-out from GSK. He led investments in CRISPR Therapeutics, Principia Biopharma, Turning Point Therapeutics and Progyny, and co-founded Nkarta Therapeutics and Arcellx.

Dren Bio secures a $350 million private financing round, oversubscribed by investors. The clinical-stage biotech company focuses on developing first-in-class antibody therapeutics. This funding supports its pipeline of antibody-based treatments in development.

Nov 2026VC News DailyNews article